Icatibanto Gp-Pharm

Icatibant, the active ingredient in Icatibanto Gp-Pharm, is a Bradykinin B2 receptor antagonist presented as a solution for injection for subcutaneous use. It treats hereditary angioedema attacks in patients with hereditary angioedema.

GNH USA supplies Icatibanto Gp-Pharm as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant is a targeted therapy for hereditary angioedema, acting on the bradykinin pathway to relieve acute swelling. - Hereditary angioedema type I: rapid relief of swelling during acute attacks. - Hereditary angioedema type II: reduces attack severity and duration. - Hereditary angioedema with normal C1-INH (HAE‑nC1‑INH): provides symptom control during attacks.

Icatibant may cause a range of adverse reactions, from mild injection‑site discomfort to rare but serious hypersensitivity events.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or erythema: localized skin reddening. - Swelling at injection site: transient edema. - Nausea: occasional gastrointestinal upset. - Headache: mild to moderate intensity. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Angioedema: unexpected swelling of face, lips, or throat. - Hypotension: sudden drop in blood pressure. - Thrombocytopenia: low platelet count. - Severe hypersensitivity: rash, fever, or organ involvement. - Injection‑site necrosis: rare tissue damage.

Before using Icatibant, consider the following safety measures. - Pregnancy: safety unknown; avoid unless benefit outweighs risk. - Breastfeeding: unknown safety; assess potential infant exposure. - Renal impairment: use with caution; monitor renal function. - Concomitant ACE inhibitors: monitor for increased bradykinin‑related effects. - Hypersensitivity: discontinue if allergic reaction occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other agents that affect bradykinin or vascular tone.

Major Interactions (Avoid): - ACE inhibitors: may increase risk of angioedema. - Renin‑angiotensin system blockers: additive bradykinin effects.

Moderate Interactions (Monitor Closely): - Estrogen‑containing contraceptives: may exacerbate hereditary angioedema. - NSAIDs: potential to increase swelling risk. - Other bradykinin‑modulating agents: monitor for additive pharmacodynamic effects.